CStone Pharmaceuticals
Total Valuation
USDAs of December 31, 2025, CSTONE PHARMACEUTICALS carries a market capitalization of 1.34B, placing it among publicly traded companies globally. Its enterprise value stands at 1.26B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.34B |
| Enterprise Value | 1.26B |
Important Dates
CSTONE PHARMACEUTICALS's next confirmed earnings release is scheduled for April 1, 2027.
| Earnings Date | 4/1/2027 |
Share Statistics
As of December 31, 2025, CSTONE PHARMACEUTICALS has 1.47B shares outstanding.
| Shares Outstanding | 1.47B |
Valuation Ratios
These figures are as of December 31, 2025.
| PB Ratio | 15.20 |
| P/TBV Ratio | 20.07 |
Financial Position
As of December 31, 2025, CSTONE PHARMACEUTICALS maintains a current ratio of 2.18, meaning it holds 2.2x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 2.18 |
| Quick Ratio | 1.80 |
| Debt / Equity | 56.51 |
Financial Efficiency
These figures cover the twelve months ended December 31, 2025.
| Employee Count | 114.00 |
Stock Price Statistics
USDAs of the close on September 30, 2026, CSTONE PHARMACEUTICALS's stock has declined approximately 24.53% over the past 52 weeks.
| 52-Week Price Change | -24.53% |
| 50-Day Moving Average | 0.57 |
Balance Sheet
USDAs of December 31, 2025, CSTONE PHARMACEUTICALS holds 131.38M in cash and equivalents against 49.84M in total debt, resulting in a net debt position of -58.82M. Total book value stands at 88.20M, with working capital of 86.23M providing operational flexibility.
| Cash & Cash Equivalents | 131.38M |
| Total Debt | 49.84M |
| Net Debt | -58.82M |
| Equity (Book Value) | 88.20M |
| Book Value Per Share | 0.06 |
| Working Capital | 86.23M |